BioAge Labs, Inc.

Contributing Author

Recent Articles by BioAge Labs, Inc.

Dec-04	BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor BIOA GlobeNewswire
Nov-25	BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference BIOA GlobeNewswire
Nov-07	BioAge Labs to Present at Jefferies Global Healthcare Conference in London BIOA GlobeNewswire
Nov-06	BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates BIOA GlobeNewswire
Aug-20	BioAge Labs to Present at Upcoming Investor Conferences BIOA GlobeNewswire
Aug-15	BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor BIOA GlobeNewswire
Aug-06	BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates BIOA GlobeNewswire
Jun-21	BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions BIOA GlobeNewswire
Jun-17	BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank BIOA GlobeNewswire
Jun-03	BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates BIOA GlobeNewswire
May-29	BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic BIOA GlobeNewswire
May-27	BioAge Labs to Present at Upcoming Investor Conferences BIOA GlobeNewswire
May-06	BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates BIOA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.